Document:

EXHIBIT 10.3
                                                                    ------------

THIS DEBENTURE, AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE (COLLECTIVELY,
THE "SECURITIES"), HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES
AND EXCHANGE COMMISSION (THE "COMMISSION") OR THE SECURITIES COMMISSION OF ANY
STATE. THE SECURITIES ARE BEING OFFERED PURSUANT TO A SAFE HARBOR FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"). THE
SECURITIES ARE "RESTRICTED" AND MAY NOT BE OFFERED OR SOLD UNLESS THE SECURITIES
ARE REGISTERED UNDER THE ACT PURSUANT TO AVAILABLE EXEMPTIONS FROM THE
REGISTRATION REQUIREMENTS OF THE ACT AND THE COMPANY WILL BE PROVIDED WITH
OPINION OF COUNSEL OR OTHER SUCH INFORMATION AS IT MAY REASONABLY REQUIRE TO
CONFIRM THAT SUCH EXEMPTIONS ARE AVAILABLE. FURTHER HEDGING TRANSACTIONS
INVOLVING THE SECURITIES MAY NOT BE MADE EXCEPT IN COMPLIANCE WITH THE ACT.

                                    DEBENTURE

                     THOMAS PHARMACEUTICAL ACQUISITION CORP.

                            10% CONVERTIBLE DEBENTURE

                              DUE JANUARY 25, 2014

NO.  2                                                                   $96,800

     This Debenture is issued by Thomas Pharmaceutical Acquisition Corp.
("Thomas Acquisition"), a _________ corporation with its principal office
located at ________________________________, to the undersigned where indicated
as Holder (together with its permitted successors and assigns, the "Holder")
pursuant to exemptions from registration under the Act.

                                   ARTICLE I.

     SECTION 1.01 PRINCIPAL AND INTEREST. For value received, on January 26,
2007, Thomas Acquisition hereby promises to pay to the order of the Holder in
lawful money of the United States of America and in immediately available funds
the principal sum of Ninety-six Thousand Eight Hundred Dollars (US $96,800) on
January 25, 2014 (the "Maturity Date"), together with interest, compounded
quarterly, on the unpaid principal of this Debenture at the rate of ten percent
(10%) per year (computed on the basis of a 365-day year and the actual days
elapsed) from the date of this Debenture until paid.

     SECTION 1.02 OPTIONAL CONVERSION. In exchange and the consideration for the
Holder purchasing this Debenture and thereby permitting Thomas Acquisition to
loan to Thomas Pharmaceuticals Ltd, (the "Company") in the aggregate One Hundred
and Sixty Thousand Dollars ($160,000) on the date hereof in the form of a Note,
the Company hereby grants to the Holder a right, at its option, to convert, and
sell on the same day, at any time and from time to

                                       1
<PAGE>

time, subject to the registration requirements of the Act, until payment in full
of this Debenture, all or any part of the principal amount of the Debenture,
plus accrued interest, into shares (the "Conversion Shares") of Series B
Convertible Preferred Stock of the Company, no par value per share ("Preferred
Stock"). Each $1,000 of the Debenture may be converted into one (1) share of
Preferred Stock using the Series B Initial Value as set forth in the Company's
Certificate of Incorporation. The full rights of the Preferred Stock are set
forth in the Certificate of Incorporation of the Company.

     No fraction of shares or scrip representing fractions of shares will be
issued on conversion, but the number of shares issuable shall be rounded to the
nearest whole share. To convert this Debenture, the Holder hereof shall deliver
written notice thereof, substantially in the form of Exhibit "A" to this
Debenture, with appropriate insertions (the "Conversion Notice"), to the Company
at its address as set forth herein. The date upon which the conversion shall be
effective (the "Conversion Date") shall be deemed to be the date set forth in
the Conversion Notice.

     SECTION 1.03 RESERVATION OF PREFERRED STOCK. The Company shall reserve and
keep available out of its authorized but unissued shares of Preferred Stock,
solely for the purpose of effecting the conversion of this Debenture, such
number of shares of Preferred Stock as shall from time to time be sufficient to
effect such conversion, based upon the Conversion Price; provided, however,
until such time as the Conversion Price has been fixed, but solely for the
purposes of this Section 1.03 only, the Conversion Price shall be deemed to be
$1,000 or, if there is a trading market for the Preferred Stock, the lowest bid
price for the preceding thirty (30) days. If at any time the Company does not
have a sufficient number of Conversion Shares authorized and available, then the
Company shall call and hold a special meeting of its stockholders within sixty
(60) days of that time for the sole purpose of increasing the number of
authorized shares of Preferred Stock.

     Section 1.04 RIGHT OF REDEMPTION. Thomas Acquisition at its option shall
have the right to redeem, with thirty (30) business days advance written notice
(the "Redemption Notice"), a portion of or the entire outstanding principal sum
under this Debenture. The redemption price shall be equal to one hundred
twenty-five percent (125%) multiplied by the portion of the principal sum being
redeemed, plus any accrued and unpaid interest. Once Thomas Acquisition has
issued to the Holder a Redemption Notice, the Holder may continue to convert
this Debenture, in accordance with Section 1.02 hereof, for the thirty (30) day
business period after the Holder receives the Redemption Notice.

     Section 1.05 REGISTRATION RIGHTS. The Company shall be under no obligation
to register the resale of the Conversion Shares under the Securities Act of
1933, as amended.

     Section 1.06 GUARANTY. Upon the occurrence of an Event of Default (as
defined in Article III hereto), this Convertible Debenture shall be immediately
due and payable. Notwithstanding anything to the contrary, the Company's
signature to this instrument shall not serve as a guaranty for the obligations
of Thomas Acquisitions, but rather shall only be enforceable against the Company
for those obligations set forth within this Debenture and expressly listed as an
obligation or covenant of the Company.

                                       2
<PAGE>

     Section 1.07 INTEREST PAYMENTS. The interest so payable will be paid at the
time of maturity or conversion to the person or company in whose name this
Debenture is registered. At the time such interest is payable, Thomas
Acquisition, in its sole discretion, may elect to pay interest in cash (via wire
transfer or certified funds) or in the form of common stock. In the event of
default, as described in Article III hereunder, the Holder may elect that the
interest be paid in cash (via wire transfer or certified funds) or in the form
of common stock. If paid in the form of common stock, the amount of stock to be
issued will be calculated as follows: the value of the stock shall be the
closing bid price on: (i) the date the interest payment is due; or (ii) if the
interest payment is not made when due, the date the interest payment is made. A
number of shares of common stock with a value equal to the amount of interest
due shall be issued. No fractional shares will be issued; therefore, in the
event that the value of the common stock per share does not equal the total
interest due, Thomas Acquisition will pay the balance in cash.

     Section 1.08 PAYING AGENT AND REGISTRAR. Initially, Thomas Acquisition will
act as paying agent and registrar. Thomas Acquisition may change any paying
agent, registrar, or Company-registrar by giving the Holder not less than ten
(10) business days' written notice of its election to do so, specifying the
name, address, telephone number and facsimile number of the paying agent or
registrar.

                                  ARTICLE II.

     SECTION 2.01 AMENDMENTS AND WAIVER OF DEFAULT. The Debenture may not be
amended without the consent of the Holder. Notwithstanding the above, without
the consent of the Holder, the Debenture may be amended to cure any ambiguity,
defect or inconsistency, to provide for assumption of Thomas Acquisition
obligations to the Holder or to make any change that does not adversely affect
the rights of the Holder.

                                  ARTICLE III.

     SECTION 3.01 EVENTS OF DEFAULT. An "Event of Default", wherever used
herein, means any one of the following events (whatever the reason and whether
it shall be voluntary or involuntary or effected by operation of law or pursuant
to any judgment, decree or order of any court, or any order, rule or regulation
of any administrative or governmental body):

    (i) Any default in the payment of the principal of, interest on or other
    charges in respect of this Debenture, free of any claim of subordination, as
    and when the same shall become due and payable and that is not cured within
    ten (10) days of Thomas Acquisition's receipt of written notice from the
    Holder explaining such default in reasonable detail (whether on an
    installment, a Principal Payment Date, an Interest Payment Date, a
    Conversion Date or the Maturity Date or by acceleration or otherwise);

    (ii) The Company and/or Thomas Acquisition shall fail to observe or perform
    any other covenant, agreement or warranty contained in, or otherwise commit
    any breach or default of any provision of this Debenture hereof which is not
    cured with in the time prescribed;

                                       3
<PAGE>

    (iii) Thomas Acquisition or any subsidiary of Thomas Acquisition shall
    commence, or there shall be commenced against Thomas Acquisition or any
    subsidiary of Thomas Acquisition under any applicable bankruptcy or
    insolvency laws as now or hereafter in effect or any successor thereto, or
    Thomas Acquisition or any subsidiary of Thomas Acquisition commences any
    other proceeding under any reorganization, arrangement, adjustment of debt,
    relief of debtors, dissolution, insolvency or liquidation or similar law of
    any jurisdiction whether now or hereafter in effect relating to Thomas
    Acquisition or any subsidiary of Thomas Acquisition or there is commenced
    against Thomas Acquisition or any subsidiary of Thomas Acquisition any such
    bankruptcy, insolvency or other proceeding which remains undismissed for a
    period of sixty one (61) days; or Thomas Acquisition or any subsidiary of
    Thomas Acquisition is adjudicated insolvent or bankrupt; or any order of
    relief or other order approving any such case or proceeding is entered; or
    Thomas Acquisition or any subsidiary of Thomas Acquisition suffers any
    appointment of any custodian, private or court appointed receiver or the
    like for it or any substantial part of its property which continues
    undischarged or unstayed for a period of sixty one (61) days; or Thomas
    Acquisition or any subsidiary of Thomas Acquisition makes a general
    assignment for the benefit of creditors; or Thomas Acquisition or any
    subsidiary of Thomas Acquisition shall fail to pay, or shall state that it
    is unable to pay, or shall be unable to pay, its debts generally as they
    become due; or Thomas Acquisition or any subsidiary of Thomas Acquisition
    shall call a meeting of its creditors with a view to arranging a
    composition, adjustment or restructuring of its debts; or Thomas Acquisition
    or any subsidiary of Thomas Acquisition shall by any act or failure to act
    expressly indicate its consent to, approval of or acquiescence in any of the
    foregoing; or any corporate or other action is taken by Thomas Acquisition
    or any subsidiary of Thomas Acquisition for the purpose of effecting any of
    the foregoing;

    (iv) Thomas Acquisition or any subsidiary of Thomas Acquisition shall
    default in any of its obligations under any other debenture or any mortgage,
    credit agreement or other facility, indenture agreement, factoring agreement
    or other instrument under which there may be issued, or by which there may
    be secured or evidenced any indebtedness for borrowed money or money due
    under any long term leasing or factoring arrangement of Thomas Acquisition
    or any subsidiary of Thomas Acquisition in an amount exceeding $20,000,
    whether such indebtedness now exists or shall hereafter be created and such
    default shall result in such indebtedness becoming or being declared due and
    payable prior to the date on which it would otherwise become due and
    payable;

    (v) The Company shall fail for any reason to deliver Preferred Stock
    certificates to a Holder prior to the fifth (5th) trading day after a
    Conversion Date or the Company shall provide notice to the Holder, including
    by way of public announcement, at any time, of its intention not to comply
    with requests for conversions of this Debenture in accordance with the terms
    hereof;

     Section 3.02 PAYMENT ON EVENT OF DEFAULT. During the time that any portion
of this Debenture is outstanding, if any Event of Default has occurred, the full
principal amount of this Debenture, together with interest and other amounts
owing in respect thereof, to the date of acceleration shall become at the
Holder's election, immediately due and payable in cash, provided however, the
Holder may request (but shall have no obligation to request) payment of

                                       4
<PAGE>

such amounts in common stock of Thomas Acquisition. Upon the occurrence of an
Event of Default, the Holder may, in its sole discretion, accelerate full
repayment of all debentures outstanding and accrued interest thereon. The Holder
need not provide and Thomas Acquisition hereby waives any presentment, demand,
protest or other notice of any kind, and the Holder may immediately and without
expiration of any grace period enforce any and all of its rights and remedies
hereunder and all other remedies available to it under applicable law. Such
declaration may be rescinded and annulled by Holder at any time prior to payment
hereunder. No such rescission or annulment shall affect any subsequent Event of
Default or impair any right consequent thereon. Upon an Event of Default,
notwithstanding any other provision of this Debenture, the Holder shall have no
obligation to Thomas Acquisition to comply with or adhere to any limitations, if
any, on the conversion of this Debenture or the sale of the Conversion Shares.

     Section 3.03 FAILURE TO ISSUE PREFERRED STOCK. The Company acknowledges
that failure to honor a Notice of Conversion shall cause irreparable harm to the
Holder.

                                  ARTICLE IV.

     SECTION 4.01 RIGHTS AND TERMS OF CONVERSION. This Debenture, in whole or in
part, may be converted at any time following the date hereof into shares of
Preferred Stock at a price equal to the Series B Initial Value as defined in the
Certificate of Incorporation of the Company.

     SECTION 4.02 RE-ISSUANCE OF DEBENTURE. When the Holder elects to convert a
part of the Debenture, then Thomas Acquisition shall reissue a new Debenture in
the same form as this Debenture to reflect the new principal amount.

                                   ARTICLE V.

     SECTION 5.01 ANTI-DILUTION. In the event that the Company shall at any time
subdivide the outstanding shares of Preferred Stock, or shall issue a stock
dividend on the outstanding Preferred Stock, the conversion price in effect
immediately prior to such subdivision or the issuance of such dividend shall be
proportionately decreased, and in the event that the Company shall at any time
combine the outstanding shares of Preferred Stock, the Conversion Price in
effect immediately prior to such combination shall be proportionately increased,
effective at the close of business on the date of such subdivision, dividend or
combination as the case may be.

                                       5
<PAGE>

                                  ARTICLE VI.

     SECTION 6.01 NOTICE. All notices or other communications required or
permitted to be given pursuant to this Debenture shall be in writing and shall
be considered as duly given on: (a) the date of delivery, if delivered in person
against written receipt therefor, or by nationally recognized overnight delivery
service or (b) five (5) days after mailing if mailed from within the continental
United States by postage pre-paid certified mail, return receipt requested to
the party entitled to receive the same:

If to Thomas Acquisition, to:          Thomas Pharmaceutical Acquisition Corp.
                                       c/o  Snow Becker Krauss P.C.
                                       605 Third Avenue
                                       New York, NY  10158
                                       Attn:   Jack Becker and Charles Snow
                                       Facsimile No.: 212-949-7052

If to the Holder:

If to the Company                      Thomas Pharmaceuticals, Inc.
                                       750 Route 34
                                       Matawan, NJ  07747
                                       Attn:  Jerome Mahoney
                                       Facsimile No.: 732-441-9895

with a copy to:                        Meritz & Muenz LLP
                                       2021 O Street, NW
                                       Washington, DC 20036
                                       Attention:  Lawrence A. Muenz, Esq.
                                       Facsimile No.: (202) 728-2910

     SECTION 6.02 GOVERNING LAW. This Debenture shall be deemed to be made under
and shall be construed in accordance with the laws of the State of New Jersey
without giving effect to the principals of conflict of laws thereof. Each of the
parties consents to the jurisdiction of the U.S. District Court sitting in the
District of the State of New Jersey or the state courts of the State of New
Jersey sitting in Hudson County, New Jersey in connection with any dispute
arising under this Debenture and hereby waives, to the maximum extent permitted
by law, any objection, including any objection based on forum non conveniens to
the bringing of any such proceeding in such jurisdictions.

                                       6
<PAGE>

     SECTION 6.03 SEVERABILITY. The invalidity of any of the provisions of this
Debenture shall not invalidate or otherwise affect any of the other provisions
of this Debenture, which shall remain in full force and effect.

     SECTION 6.04 ENTIRE AGREEMENT AND AMENDMENTS. This Debenture represents the
entire agreement between the parties hereto with respect to the subject matter
hereof and there are no representations, warranties or commitments, except as
set forth herein. This Debenture may be amended only by an instrument in writing
executed by the parties hereto.

     Section 6.05 RELEASE. In consideration for entering into this Debenture,
the Company, Thomas Acquisition, iVoice, Inc. and the Holder, on the date
hereof, knowingly, voluntarily and unconditionally release, forever discharge,
and covenant not to sue the other parties hereto from or for any and all claims,
causes of action, demands, suits, debts, obligations, liabilities, damages,
losses, costs and expenses (including attorneys' fees) of every kind or nature
whatsoever, known or unknown, actual or potential, suspected or unsuspected,
fixed or contingent, that such party has or may have, now or in the future to
the end of the world, arising out of, relating to, or resulting from any act or
omission, error, negligence, breach of contract, tort, violation of law,
discrimination, matter or cause whatsoever from the beginning of time or in the
future to the end of the world; provided, however, that the foregoing release
shall not apply to any claims arising out of this Debenture. Each party hereto
agrees that notwithstanding anything else in this Debenture, the provisions of
this Section 6.05 shall survive termination of this Debenture.

     IN WITNESS WHEREOF, with the intent to be legally bound hereby, Thomas
Acquisition as executed this Debenture as of the date first written above.

                                       THOMAS PHARMACEUTICAL ACQUISITION CORP.

                                       By:
                                           -------------------------------------
                                            Name:
                                                  ------------------------------
                                            Title:
                                                   -----------------------------

                                       THOMAS PHARMACEUTICALS, LTD.
                                       By:
                                           -------------------------------------
                                            Name:
                                                  ------------------------------
                                            Title:
                                                   -----------------------------

                                       IVOICE, INC.
                                       [Limited to Section 6.05 only]

                                       By:
                                           -------------------------------------
                                            Name:
                                                  ------------------------------
                                            Title:
                                                   -----------------------------

                                       7
<PAGE>

                                       HOLDER

                                       By:
                                           -------------------------------------
                                            Name:
                                                  ------------------------------
                                            Title:
                                                   -----------------------------

                                       8
<PAGE>

                                   EXHIBIT "A"
                                   -----------

                              NOTICE OF CONVERSION
                              --------------------

           (TO BE EXECUTED BY THE HOLDER IN ORDER TO CONVERT THE NOTE)

TO:

     The undersigned hereby irrevocably elects to convert $ ___________________
of the principal amount of this Debenture into Shares of Preferred Stock of
Thomas Pharmaceuticals Inc., according to the conditions stated therein, as of
the Conversion Date written below.

CONVERSION DATE:               _________________________________________________

APPLICABLE CONVERSION PRICE:   _________________________________________________

SIGNATURE:                     _________________________________________________

NAME:                          _________________________________________________

ADDRESS:                       _________________________________________________

AMOUNT TO BE CONVERTED:  $     _________________________________________________

AMOUNT OF DEBENTURE
UNCONVERTED: $                 _________________________________________________

CONVERSION PRICE PER SHARE: $  _________________________________________________

NUMBER OF SHARES OF PREFERRED
STOCK TO BE ISSUED:            _________________________________________________

PLEASE ISSUE THE SHARES OF
PREFERRED STOCK IN THE FOLLOWING
NAME AND TO THE FOLLOWING
ADDRESS:                       _________________________________________________

ISSUE TO:                      _________________________________________________

AUTHORIZED SIGNATURE:          _________________________________________________

NAME:                          _________________________________________________

TITLE:                         _________________________________________________

PHONE NUMBER:                  _________________________________________________

BROKER DTC PARTICIPANT CODE:   _________________________________________________

ACCOUNT NUMBER:                _________________________________________________

ADDRESS OF RECEIVING PARTY:    _________________________________________________

SOCIAL SECURITY NUMBER OR TAX
IDENTIFICATION NUMBER OF
RECEIVING PARTY:               _________________________________________________EXHIBIT 10.4
                                                                    ------------

                                 PROMISSORY NOTE
                                 ---------------
                                                             Matawan, New Jersey
                                                                January 26, 2007

$160,000

          FOR VALUE RECEIVED, the undersigned ("Maker"), hereby unconditionally
promises to pay to the order of Thomas Pharmaceutical Acquisition Corp. (the
"Payee"), with offices at ____________________________ or at such other place as
the Payee or any holder hereof may from time to time designate, the aggregate
principal sum of One Hundred Sixty Thousand Dollars ($160,000) in lawful money
of the United States and in immediately available funds, and such additional
amounts that may be advanced by the holder hereof and such advances will be
added to the principal sum of this Promissory Note and will accrue interest at
the specified rate of interest from the date of advance until paid in full.
Unless otherwise provided, this Promissory Note may be prepaid in full or in
part at any time without penalty or premium. The term of this Promissory Note
shall be seven (7) years and shall be due and payable on January 8, 2014.

          Maker hereby further promises to pay interest to the order of Payee in
like money at said office or place on the unpaid principal balance hereof
computed at a rate of ten percent (10%) per annum at a rate, upon and after an
Event of Default (as hereinafter defined), of eighteen percent (18%) per annum.
Interest shall be calculated on the basis of a three hundred sixty (360) day
year and actual days elapsed. In no event shall the interest charged hereunder
exceed the maximum permitted under the laws of the State of New York. The Maker
shall make principal payments to the Payee from time to time as it may decide in
its sole discretion.

In the event of (a) default in payment of any installment of principal or
interest hereof as the same becomes due and such default is not cured within ten
(10) days from the due date, or (b) default under the terms of any instrument
securing this Promissory Note, and such default is not cured within fifteen (15)
days after written notice to the Maker, then in either such event the holder
may, without further notice, declare the remainder of the principal sum,
together with all interest accrued thereon, and the prepayment premium, if any,
at once due and payable (an "Event of Default"). Failure to exercise this option
shall not constitute a waiver of the right to exercise the same at any other
time.

          The provisions of this Promissory Note may not be changed, modified or
terminated orally, but only by an agreement in writing signed by the party to be
charged, nor shall any waiver be applicable except in the specific instance for
which it is given.
<PAGE>
          Maker hereby waives all rights to trial by jury in any action or
proceeding instituted by either Maker or Payee against the other arising on, out
of or by reason of this Promissory Note, any alleged tortious conduct by Maker
or Payee or in any way, directly or indirectly, arising out of or related to the
relationship between Maker and Payee. In no event will Payee be liable for lost
profits or other special or consequential damages.

          Upon default, the holder of this Promissory Note may employ an
attorney to enforce the holder's rights and remedies and the, principal, surety,
guarantor and endorsers of this Promissory Note hereby agree to pay to the
holder reasonable attorney's fees, plus all other reasonable expenses incurred
by the holder in exercising any of the holder's right and remedies upon default.
The failure to exercise any such right or remedy shall not be a waiver or
release of such rights or remedies or the right to exercise any of them at
another time.

          Maker hereby waives all rights to interpose any claims, deductions,
setoffs or counterclaims of any kind, nature or description in any action or
proceeding instituted by Maker with respect to this Promissory Note or any
matter arising herefrom or relating hereto, except compulsory counterclaims.

          Maker hereby irrevocably submits and consents to the non-exclusive
jurisdiction of the State and Federal Courts located in the State of New York
with respect to any action or proceeding arising out of this Promissory Note or
any matter arising herefrom or relating hereto. Any such action or proceeding
commenced by Maker against Payee will be litigated only in a Federal Court or a
State Court located in Suffolk County New York and Maker waives any objection
based on forum non-conveniens and any objection to venue in connection
therewith.

          Service of process or notice in connection with any proceedings may be
served (i) inside or outside the State in which the office of Payee indicated
above is located by registered or certified mail, return receipt requested,
addressed to the Maker and service or notice so served shall be deemed complete
five (5) days after the same shall have been posted, or (ii) in such manner as
may be permissible under the rules of said Courts.

          The execution and delivery of this Promissory Note has been authorized
by the Board of Directors of Maker. This Promissory Note shall be governed by
and construed, and all rights and obligations hereunder determined, in
accordance with the internal laws of the State of New Jersey and shall be
binding upon the successors and assigns of the Maker and inure to the benefit of
the Payee, its successors, endorsees and assigns. If the undersigned are more
than one, this Promissory Note shall be binding jointly and severally upon the
undersigned and their respective successors and assigns and the term "Maker"
shall mean, individually and collectively, all the undersigned and any one or
more of them and their successors and assigns. If any term or provision of this
Promissory Note shall be held invalid, illegal or unenforceable, the validity of
all other terms and provisions hereof shall in no way be affected thereby.

                                        2
<PAGE>

IN TESTIMONY WHEREOF, each corporate maker has caused this instrument to be
executed in its corporate name by a corporate officer, and its corporate seal to
be hereto affixed, all by order of its Board of Directors first duly given, the
day and year first written below:

THOMAS PHARMACEUTICALS LTD.

By: _________________________                        Dated:    January 31, 2007

                                        3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00116-of-00352.parquet"}]]